Compare Heron Therapeutics Inc (HRTX) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Teradyne, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Teradyne, Inc. trades at $378.39 (market cap $52.25B). The key difference: Teradyne, Inc. is far larger — about 571.3× Heron Therapeutics Inc's market cap, and Teradyne, Inc. pays a 0.16% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | TER | |
|---|---|---|
Market Cap | $91.46M | $52.25B |
Sector | Health | Technology |
52-Week High | $1.96 | $483.84 |
52-Week Low | $0.39 | $90.15 |
Enterprise Value | $189.36M | $52.08B |
Dividend Yield | — | 0.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Teradyne (TER) trades at $334.23, up 3.68% on the day, with strong recent earnings beats and robust AI-driven semiconductor testing demand. The stock shows bearish technical signals but benefits from high profitability margins (net income margin 22.55%) and consistent revenue growth, projected to reach $3.8B in 2026. Analysts maintain a bullish consensus with a $453.60 price target, citing AI infrastructure expansion and recent product launches as key catalysts.
Outlook remains positive given TER's strategic positioning in AI and semiconductor testing, though elevated valuation ratios (P/E 59.81) and technical bearishness pose near-term risks. Investment opportunity hinges on execution in high-growth AI segments, while risks include market volatility and competitive pressures in the chip equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
